EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Current Biomarker Strategies in Autoimmune Neuromuscular Diseases

Menekse Oeztuerk, Antonia Henes, Christina B Schroeter, Christopher Nelke, Paula Quint, Lukas Theissen, Sven G Meuth, Tobias Ruck iD

Cells · 2023

DOI: 10.3390/cells12202456 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, 2023. Verfasst von Menekse Oeztuerk und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany. Hauptthemen laut MEDLINE: Neuromuscular Diseases, Guillain-Barre Syndrome, Myasthenia Gravis, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heinrich Heine University Düsseldorf.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory neuromuscular disorders encompass a diverse group of immune-mediated diseases with varying clinical manifestations and treatment responses. The identification of specific biomarkers has the potential to provide valuable insights into disease pathogenesis, aid in accurate diagnosis, predict disease course, and monitor treatment efficacy. However, the rarity and heterogeneity of these disorders pose significant challenges in the identification and implementation of reliable biomarkers. Here, we aim to provide a comprehensive review of biomarkers currently established in Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis (MG), and idiopathic inflammatory myopathy (IIM). It highlights the existing biomarkers in these disorders, including diagnostic, prognostic, predictive and monitoring biomarkers, while emphasizing the unmet need for additional specific biomarkers. The limitations and challenges associated with the current biomarkers are discussed, and the potential implications for disease management and personalized treatment strategies are explored. Collectively, biomarkers have the potential to improve the management of inflammatory neuromuscular disorders. However, novel strategies and further research are needed to establish clinically meaningful biomarkers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuromuscular DiseasesGuillain-Barre SyndromeMyasthenia GravisPolyradiculoneuropathy, Chronic Inflammatory DemyelinatingImmune System DiseasesHumansBiomarkers

Stichwörter der Autor:innen

CIDPGBSIIMbiomarkersinflammationmyasthenia gravisneuromuscular diseases

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Neurology, Medical Faculty, Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany.

ORCID-Profile: Tobias Ruck

Förderung

  • Heinrich Heine University Düsseldorf

Zitieren

APA

Oeztuerk, M., Henes, A., Schroeter, C. B., Nelke, C., Quint, P., Theissen, L., Meuth, S. G., & Ruck, T. (2023). Current Biomarker Strategies in Autoimmune Neuromuscular Diseases. Cells. https://doi.org/10.3390/cells12202456

Vancouver

Oeztuerk M, Henes A, Schroeter CB, Nelke C, Quint P, Theissen L, et al. Current Biomarker Strategies in Autoimmune Neuromuscular Diseases. Cells. 2023. doi:10.3390/cells12202456

BibTeX
@article{Oeztuerk2023,
  author = {Oeztuerk, Menekse and Henes, Antonia and Schroeter, Christina B and Nelke, Christopher and Quint, Paula and Theissen, Lukas and Meuth, Sven G and Ruck, Tobias},
  title = {Current Biomarker Strategies in Autoimmune Neuromuscular Diseases},
  journal = {Cells},
  year = {2023},
  doi = {10.3390/cells12202456}
}
Kostenlos starten →